Determination of the norepinephrine level by high-performance liquid chromatography to assess the protective effect of MAO-B inhibitors against DSP-4 toxicity

Journal of Chromatographic Science

Volumn 40, Issue 9, 2002, Pages 495-499

  Haberle, Diana ^a   Magyar, Kálmán ^a   Szökő, Éva ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; BENZYLAMINE DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEUROTOXIN; NORADRENALIN;

ANIMAL; ANIMAL TISSUE; ARTICLE; CHEMISTRY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; ELECTROCHEMISTRY; ENZYME INHIBITION; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; METHODOLOGY; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; RISK ASSESSMENT; SAMPLING; TECHNOLOGY;

ANIMALS; BENZYLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; HIPPOCAMPUS; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; NEUROTOXINS; NOREPINEPHRINE;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0036802075     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/40.9.495     Document Type: Article

References (34)

1. N.E. Anden, A. Dahlstrom, K. Fuxe, L. Olson, and U. Ungerstedt. Ascending noradrenaline neurons from the pons and the medulla oblongata. Experientia 22(1): 44-45 (1966).
2. U. Ungerstedt. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl. 367: 1-48 (1971).
3. E.L. Arnold and R. Ford. Determination of catechol-containing compounds in tissue samples by gas-liquid chromatography. Anal. Chem. 45(1): 85-89 (1973).
4. I.L. Martin and G.B. Ansell. A sensitive gas chromatographic procedure for the estimation of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain. Biochem. Pharmacol. 22(4): 521-33 (1973).
5. S.H. Koslow, F. Cattabeni, and E. Costa. Norepinephrine and dopamine: Assay by mass fragmentography in the picomole range. Science 176(31): 177-80 (1972).
6. J.-C. Lhuguenot and B.F. Maume. Improvements in quantitative gas phase analysis of catecholamines in the picomole range by electron-capture detection and mass fragmentography of their pentafluorobenzylimine-trimethylsilyl derivatives. J. Chromatogr. Sci. 12(7): 411-18 (1974).
7. L.D. Mell and A.B. Gustafson. Urinary free norepinephrine and dopamine determined by reverse-phase high-pressure liquid chromatography. Clin. Chem. 23(3): 473-76 (1977).
8. K. Imai, M. Tsukamoto, and Z. Tamara. High-performance liquid chromatographic assay of rat-brain dopamine and norepinephrine. J. Chromatogr. 137(2): 357-62 (1977).
9. C. Refshauge, P.T. Kissinger, R. Dreiling, L. Blank, R. Freeman, and R.N. Adams. New high performance liquid chromatographic analysis of brain catecholamines. Life Sci. 14(2): 311-22 (1974).
10. P.T. Kissinger, C.S. Bruntlett, G.C. Davis, L.J. Felice, R.M. Riggin, and R.E. Shoup. Recent developments in the clinical assessment of the metabolism of aromatics by high-performance, reversed-phase chromatography with amperometric detection. Clin. Chem. 23(8): 1449-55 (1977).
11. K. Engelman and B. Portnoy. A sensitive double-isotope derivative assay for norepinephrine and epinephrine. Normal resting human plasma levels. Circ. Res. 26(1): 53-57 (1970).
12. G.A. Johnson, C.A. Baker, and R.T. Smith. Radioenzymatic assay of sulfate conjugates of catecholamines and DOPA in plasma. Life Sci. 26(19): 1591-98 (1980).
13. S.B. Ross and A.L. Renyi. On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active uptake of noradrenaline. J. Pharm. Pharmacol. 28: 458-59 (1976).
14. G. Jaim-Etcheverry and L.M. Zieher. DSP-4: A novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain. Res. 188: 513-23 (1980).
15. R. Wurtman and I. Axelrod. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem. Pharmacol. 12: 1414-19 (1963).
16. K. Magyar. Monoamine Oxidases and Their Selective Inhibition. Akadémia Kiadó, Budapest, Hungary, 1980, pp. 11-21.
17. P.T. Kissinger, R.M. Riggin, R.L. Alcorn, and L.D. Rau. Estimation of catecholamines in urine by high performance liquid chromatography with electrochemical detection. Biochem. Med. 13(4): 299-306 (1975).
18. L.J. Felice and P.T. Kissinger. Determination of homovanillic acid in urine by liquid chromatography with electrochemical detection. Anal. Chem. 48(6): 794-96 (1976).
19. R. Keller, A. Oke, I. Mefford, and R.N. Adams. Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci. 19(7): 995-1003 (1976).
20. S. Sasa and C.L. Blank. Determination of serotonin and dopamine in mouse brain tissue by high performance liquid chromatography with electrochemical detection. Anal. Chem. 49(3): 354-59 (1977).
21. R. Grzanna, U. Berger, J.M. Fritschy, and M. Geffard. Acute action of DSP-4 on central norepinephrine axons: Biochemical and immunohistochemical evidence for differential effects. J. Histochem. Cytochem. 37: 1435-42 (1989).
22. L.M. Zieher and G. Jaim-Etcheverry. Neurotoxicity of N-(2-chloroethyl)-N-ethyl-2-bromo-benzylamine hydrochloride (DSP 4) on noradrenergic neurons is mimicked by its cyclic aziridinium derivative. Eur. J. Pharmacol. 65: 249-56 (1980).
23. J. Knoll and K. Magyar. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5: 393-408 (1972).
24. W. Birkmayer, J. Knoll, P. Riederer, M.B. Youdim, V. Hars, and J. Marton. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J. Neural. Transm. 64: 113-27 (1985).
25. R.E. Heikkila, L. Manzino, F.S. Cabbat, and R.C. Duvoisin. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (5985): 467-69 (1984).
26. K.T. Finnegan, J.J. Skratt, I. Irwin, L.E. DeLanney, and J.W. Langston. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol. 184: 119-26 (1990).
27. L.G. Harsing, Jr., K. Magyar, K. Tekes, E.S. Vizi, and J. Knoll. Inhibition by deprenyl of dopamine uptake in rat striatum: A possible correlation between dopamine uptake and acetylcholine release inhibition. Pol. J. Pharmacol. Pharm. 31: 297-307 (1979).
28. K. Tekes, L. Tothfalusi, J. Gaal, and K. Magyar. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol. J. Pharmacol. Pharm. 40: 653-58 (1988).
29. T. Yoshida, Y. Yamada, T. Yamamoto, and Y. Kuroiwa. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16: 129-36 (1986).
30. É. Szöko and K. Magyar. Enantiomer identification of the major metabolites of (-)-deprenyl in rat urine by capillary electrophoresis. Int. J. Pharmaceut. Adv. 1: 320-28 (1996).
31. H. Kalász, L. Kerecsen, J. Knoll, and J. Pucsok. Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. J. Chromatogr. 499: 589-99 (1990).
32. K. Magyar. Behaviour of (-)-deprenyl and its analogues. J. Neural. Transm. 41S: 167-75 (1994).
33. R.E. Heikkila, H. Orlansky, C. Mytilineou, and G. Cohen. Amphetamine: Evaluation of D- and L-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J. Pharmacol. Exp. Ther. 194: 47-56 (1975).
34. K. Magyar. The role of the metabolism of (-)-deprenyl in neuroprotection. Proceedings of the 11th ESN meeting. A.W. Teelken and J. Korf, Eds. Neurochemistry 51: 303-308 (1997).